Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000908834-25-000055
Filing Date
2025-02-10
Accepted
2025-02-10 12:47:20
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 42429
2 JOINT ACQUISITION STATEMENT jas.htm EX-1 9321
  Complete submission text file 0000908834-25-000055.txt   53761
Mailing Address C/O FARALLON PARTNERS, L.L.C. ONE MARITIME PLAZA, SUITE 2100 SAN FRANCISCO CA 94111
Business Address C/O FARALLON PARTNERS, L.L.C. ONE MARITIME PLAZA, SUITE 2100 SAN FRANCISCO CA 94111 (415) 421-2132
Farallon Capital Partners, L.P. (Filed by) CIK: 0001175707 (see all company filings)

EIN.: 943106322 | State of Incorp.: CA | Fiscal Year End: 1231
Type: SCHEDULE 13G/A

Mailing Address 3060 PEGASUS PARK DRIVE BUILDING 6 DALLAS TX 75247
Business Address 3060 PEGASUS PARK DRIVE BUILDING 6 DALLAS TX 75247 (310) 618-6994
Forte Biosciences, Inc. (Subject) CIK: 0001419041 (see all company filings)

EIN.: 261243872 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-89959 | Film No.: 25604747
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)